Company profile: NeurogesX
1.1 - Company Overview
Company description
- Provider of therapies for chronic peripheral neuropathic pain through development and commercialization.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NeurogesX
GeNeuro
HQ: Switzerland
Website
- Description: Provider of therapeutic monoclonal antibody drugs targeting human endogenous retroviral proteins for nervous system and autoimmune diseases. Portfolio includes Temelimab for Multiple Sclerosis and long-COVID neurological/psychiatric symptoms, the GNC-501 personalized trial in post-COVID W-ENV-positive patients, and a preclinical HERV-K Env antibody for sporadic ALS.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GeNeuro company profile →
Gilgamesh Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel psychotropic and psychedelic-inspired medicines for depression, bipolar depression, anxiety, stress-related disorders, and other conditions, developing compounds optimized for safety, tolerability, duration, and efficacy, including GM-1020 (oral, rapid-acting, non-dissociative NMDAR antagonist for potential at-home use), GM-2505 (short-acting 5-HT2A agonist), GM-5022 (non-hallucinogenic neuroplastogen), and GM-3009 (safer ibogaine analog for opioid use disorder, PTSD, and TBI).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gilgamesh Pharmaceuticals company profile →
LB Pharmaceuticals
HQ: United States
Website
- Description: Provider of development-stage CNS therapeutics focused on LB-102 (n-Methyl amisulpride), a modified amisulpride for schizophrenia, and clinical trials assessing its safety, efficacy, and pharmacokinetics. Also develops improved versions of CNS treatments widely used overseas but not FDA approved for commercialization in the United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LB Pharmaceuticals company profile →
Quiver Bioscience
HQ: United States
Website
- Description: Provider of human disease models using stem cell and CRISPR engineering for high-throughput screening; proprietary optogenetic electrophysiology and software to measure neuronal activity; AI/ML analytics to decode CNS biology and identify disease phenotypes and candidates; and drug discovery combining single-cell imaging, multi-omics and proprietary engineering to create transformational medicines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quiver Bioscience company profile →
Xanodyne
HQ: United States
Website
- Description: Provider of integrated specialty pharmaceutical products, developing and commercializing offerings in women's healthcare and pain management in the United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xanodyne company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NeurogesX
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NeurogesX
2.2 - Growth funds investing in similar companies to NeurogesX
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NeurogesX
4.2 - Public trading comparable groups for NeurogesX
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →